About
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Current Value
$1.111 Year Return
Current Value
$1.111 Year Return
Key Details
Market Cap
$146.53M
P/E Ratio
-0.36
1Y Stock Return
-86.14%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
0.8
Stock's related to RAPT
The stocks that are correlated to RAPT - Rapt Therapeutics, Inc. are PLYA, RUM, DESP, HMC, AVXL
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 65.05% | $1.70B | +41.21% | 0.00% | |
R RUMRumble, Inc. | 57.47% | $2.60B | +15.29% | 0.00% |
D DESPDespegar.com Corp. | 47.86% | $1.58B | +64.72% | 0.00% |
| 38.36% | $40.73B | -27.24% | 2.70% | |
| 38.18% | $706.03M | +85.27% | 0.00% | |
| 29.25% | $32.68M | -84.03% | 0.00% | |
| 28.33% | $1.93B | -44.90% | 0.00% | |
| 26.80% | $1.10B | -62.95% | 0.00% | |
C COHUCohu, Inc. | 26.77% | $640.86M | -56.61% | 0.00% |
| 26.72% | $23.87B | -22.46% | 1.15% | |
G GCMGGCM Grosvenor, Inc. | 26.35% | $578.91M | +38.01% | 3.49% |
| 26.20% | $19.00B | -31.97% | 0.00% | |
| 25.87% | $2.69B | -10.69% | 0.00% | |
| 25.79% | $76.31M | +27.52% | 0.00% | |
C CTSCTS Corp. | 25.52% | $1.12B | -15.85% | 0.44% |
M MERC.UMercer International, Inc. | 25.27% | $352.41M | -46.93% | 6.00% |
| 25.27% | $523.67M | -76.13% | 21.71% | |
| 25.20% | $47.67M | -68.09% | 0.00% | |
| 25.16% | $1.88B | -76.84% | 1.58% | |
| 25.15% | $21.89B | -52.81% | 4.66% | |
ETF's related to RAPT
The ETFs that are correlated to RAPT - Rapt Therapeutics, Inc. are ETH, CETH, ETHA, ETHW, ETHV
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 37.31% | $1.29B | 0% | |
| 37.28% | $10.46M | 0% | |
| 37.01% | $2.25B | 0.25% | |
| 36.90% | $178.38M | 0% | |
| 36.76% | $87.80M | 0% | |
| 36.68% | $14.37M | 0.25% | |
| 36.62% | $761.54M | 0.25% | |
| 36.47% | $22.41M | 0% | |
| 33.88% | $3.28B | 0.15% | |
| 33.39% | $33.02M | 0.69% | |
| 32.10% | $294.73M | 0% | |
| 31.21% | $188.92M | 0% | |
X XBISPDR Biotech ETF | 29.79% | $5.06B | 0.35% |
| 28.52% | $5.70B | 0.45% | |
| 27.04% | $48.65M | 0.69% | |
| 26.40% | $3.28B | 0.39% | |
| 25.95% | $1.05B | 0.35% | |
| 25.93% | $229.13M | 0.58% | |
| 25.44% | $362.92M | 0.35% | |
| 25.18% | $813.28M | 0.79% | |
News
Yahoo
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: Leerink Global Healthcare Conference – Fireside chat on Tuesday, March 11, 2
Yahoo
SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. “Our focus for 2025 will be on advancing development of RPT904, a novel, potentia
Yahoo
The company carried out the trial in partnership with MSD and RAPT Therapeutics.
SeekingAlpha
RAPT Therapeutics pivoted from a failed inflammation asset (RPT193) to focus on RPT904 for food allergies. Find out whether RAPT stock is a buy.
Yahoo
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:0
Yahoo
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds